# A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

> **NCT00715182** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 87 (actual)

## Conditions studied

- Advanced/ Metastatic Renal Cell Cancer

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT00715182
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00715182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00715182, "A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00715182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*